Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management
Objective: To examine the perioperative impact of factor V Leiden mutation on thromboembolic events' risk in radical prostatectomy (RP) patients. With an incidence of about 5%, factor V Leiden mutation is the most common hereditary hypercoagulability among Caucasians and rarer in Asia. The incr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388222000534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850212715735285760 |
|---|---|
| author | Randi M. Pose Sophie Knipper Jonas Ekrutt Mara Kölker Pierre Tennstedt Hans Heinzer Derya Tilki Florian Langer Markus Graefen |
| author_facet | Randi M. Pose Sophie Knipper Jonas Ekrutt Mara Kölker Pierre Tennstedt Hans Heinzer Derya Tilki Florian Langer Markus Graefen |
| author_sort | Randi M. Pose |
| collection | DOAJ |
| description | Objective: To examine the perioperative impact of factor V Leiden mutation on thromboembolic events' risk in radical prostatectomy (RP) patients. With an incidence of about 5%, factor V Leiden mutation is the most common hereditary hypercoagulability among Caucasians and rarer in Asia. The increased risk of thromboembolic events is three- to seven-fold in heterozygous and to 80-fold in homozygous patients. Methods: Within our prospectively collected database, we analysed 33 006 prostate cancer patients treated with RP between December 2001 and December 2020. Of those, patients with factor V Leiden mutation were identified. All patients received individualised recommendation of haemostaseologists for perioperative anticoagulation. Thromboembolic complications (deep vein thrombosis and pulmonary embolism) were assessed during hospital stay, as well as according to patient reported outcomes within the first 3 months after RP. Results: Overall, 85 (0.3%) patients with known factor V Leiden mutation were identified. Median age was 65 (interquartile range: 61–68) years. There was at least one thrombosis in 53 (62.4%) patients and 31 (36.5%) patients had at least one embolic event in their medical history before RP. Within all 85 patients with factor V Leiden mutation, we experienced no thromboembolic complications within the first 3 months after surgery. Conclusion: In our cohort of patients with factor V Leiden mutation, no thromboembolic events were observed after RP with an individualised perioperative coagulation management concept. This may reassure patients with this hereditary condition who are counselled for RP. |
| format | Article |
| id | doaj-art-887f5dbeb65148c69d3cc6615ea86d8e |
| institution | OA Journals |
| issn | 2214-3882 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-887f5dbeb65148c69d3cc6615ea86d8e2025-08-20T02:09:17ZengElsevierAsian Journal of Urology2214-38822024-01-01111424710.1016/j.ajur.2022.01.007Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation managementRandi M. Pose0Sophie Knipper1Jonas Ekrutt2Mara Kölker3Pierre Tennstedt4Hans Heinzer5Derya Tilki6Florian Langer7Markus Graefen8Martini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Germany; Corresponding author.Martini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, GermanyDepartment of Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, GermanyMartini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, GermanyObjective: To examine the perioperative impact of factor V Leiden mutation on thromboembolic events' risk in radical prostatectomy (RP) patients. With an incidence of about 5%, factor V Leiden mutation is the most common hereditary hypercoagulability among Caucasians and rarer in Asia. The increased risk of thromboembolic events is three- to seven-fold in heterozygous and to 80-fold in homozygous patients. Methods: Within our prospectively collected database, we analysed 33 006 prostate cancer patients treated with RP between December 2001 and December 2020. Of those, patients with factor V Leiden mutation were identified. All patients received individualised recommendation of haemostaseologists for perioperative anticoagulation. Thromboembolic complications (deep vein thrombosis and pulmonary embolism) were assessed during hospital stay, as well as according to patient reported outcomes within the first 3 months after RP. Results: Overall, 85 (0.3%) patients with known factor V Leiden mutation were identified. Median age was 65 (interquartile range: 61–68) years. There was at least one thrombosis in 53 (62.4%) patients and 31 (36.5%) patients had at least one embolic event in their medical history before RP. Within all 85 patients with factor V Leiden mutation, we experienced no thromboembolic complications within the first 3 months after surgery. Conclusion: In our cohort of patients with factor V Leiden mutation, no thromboembolic events were observed after RP with an individualised perioperative coagulation management concept. This may reassure patients with this hereditary condition who are counselled for RP.http://www.sciencedirect.com/science/article/pii/S2214388222000534Prostate cancerProstatectomyFactor V Leiden mutationThromboembolismThrombophilia |
| spellingShingle | Randi M. Pose Sophie Knipper Jonas Ekrutt Mara Kölker Pierre Tennstedt Hans Heinzer Derya Tilki Florian Langer Markus Graefen Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management Asian Journal of Urology Prostate cancer Prostatectomy Factor V Leiden mutation Thromboembolism Thrombophilia |
| title | Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management |
| title_full | Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management |
| title_fullStr | Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management |
| title_full_unstemmed | Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management |
| title_short | Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management |
| title_sort | prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor v leiden mutation by multidisciplinary coagulation management |
| topic | Prostate cancer Prostatectomy Factor V Leiden mutation Thromboembolism Thrombophilia |
| url | http://www.sciencedirect.com/science/article/pii/S2214388222000534 |
| work_keys_str_mv | AT randimpose preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT sophieknipper preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT jonasekrutt preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT marakolker preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT pierretennstedt preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT hansheinzer preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT deryatilki preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT florianlanger preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement AT markusgraefen preventionofthromboemboliceventsafterradicalprostatectomyinpatientswithhereditarythrombophiliaduetoafactorvleidenmutationbymultidisciplinarycoagulationmanagement |